Zhao Rongchuan, Zhou Yuanshuai, Zhang Hong, Pan Jinlin, Yang Fan, Zhang Ruobing, Ahmad Nafees, Yang Jiao, Sun Minxuan
Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China.
School of Biomedical Engineering (Suzhou), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China.
J Clin Med. 2022 Jun 24;11(13):3662. doi: 10.3390/jcm11133662.
Glioblastoma multiforme (GBM) is an aggressive brain tumor with high risks of recurrence and mortality. Chemoradiotherapy resistance has been considered a major factor contributing to the extremely poor prognosis of GBM patients. Therefore, there is an urgent need to develop highly effective therapeutic agents. Here, we demonstrate the anti-tumor effect of morusin, a typical prenylated flavonoid, in GBM through in vivo and in vitro models. Morusin showed selective cytotoxicity toward GBM cell lines without harming normal human astrocytes when the concentration was less than 20 µM. Morusin treatment significantly induced apoptosis of GBM cells, accompanied by the activation of endoplasmic reticulum (ER) stress, and the appearance of cytoplasmic vacuolation and autophagosomes in cells. Then, we found the ER stress activation and cytotoxicity of morusin were rescued by ER stress inhibitor 4-PBA. Furthermore, morusin arrested cell cycle at the G1 phase and inhibited cell proliferation of GBM cells through the Akt-mTOR-p70S6K pathway. Dysregulation of ERs and cell cycle in morusin exposed GBM cells were confirmed by RNA-seq analysis. Finally, we demonstrated the combination of morusin and TMZ remarkably enhanced ER stress and displayed a synergistic effect in GBM cells, and suppressed tumor progression in an orthotopic xenograft model. In conclusion, these findings reveal the toxicity of morusin to GBM cells and its ability to enhance drug sensitivity to TMZ, suggesting the potential application value of morusin in the development of therapeutic strategies for human GBM.
多形性胶质母细胞瘤(GBM)是一种侵袭性脑肿瘤,具有高复发风险和高死亡率。放化疗耐药性被认为是导致GBM患者预后极差的主要因素。因此,迫切需要开发高效的治疗药物。在此,我们通过体内和体外模型证明了典型的异戊烯基黄酮桑色素对GBM的抗肿瘤作用。当浓度低于20μM时,桑色素对GBM细胞系表现出选择性细胞毒性,而不损害正常人星形胶质细胞。桑色素处理显著诱导GBM细胞凋亡,伴随着内质网(ER)应激的激活,以及细胞中细胞质空泡化和自噬体的出现。然后,我们发现ER应激抑制剂4-PBA可挽救桑色素的ER应激激活和细胞毒性。此外,桑色素使细胞周期停滞在G1期,并通过Akt-mTOR-p70S6K途径抑制GBM细胞的增殖。RNA测序分析证实了桑色素处理的GBM细胞中内质网和细胞周期的失调。最后,我们证明桑色素与替莫唑胺(TMZ)联合使用可显著增强ER应激,并在GBM细胞中显示出协同作用,并在原位异种移植模型中抑制肿瘤进展。总之,这些发现揭示了桑色素对GBM细胞的毒性及其增强对TMZ药物敏感性的能力,表明桑色素在人类GBM治疗策略开发中的潜在应用价值。